8-K: Hims & Hers Health Expands Board with Appointment of Deb Autor

Hims & Hers Health, Inc. has increased its board size and appointed Deb Autor as a new independent director, effective immediately.

Summary

• Hims & Hers Health, Inc. has increased the size of its board of directors from nine to ten members.
• Deb Autor, aged 57, has been appointed to fill the newly created board vacancy, effective November 15, 2024.
• Ms. Autor will serve until the company's 2025 annual meeting of stockholders.
• The board has determined that Ms. Autor meets the requirements for independence under the New York Stock Exchange listing standards.
• Ms. Autor will receive compensation as outlined in the company's proxy statement filed on April 26, 2024.
• Ms. Autor has also entered into a consulting agreement with the company for a one-year period, receiving a $100,000 consulting fee.
• The consulting agreement can be terminated with 30 days' notice without cause, or 15 days' notice for a curable material breach.
• Ms. Autor has also entered into the company's standard form of indemnification agreement.
• Ms. Autor has been appointed to the Risk Committee of the Board, effective November 15, 2024.
• Other directors appointed to the Risk Committee include Christopher Payne, Anja Manuel, Kre Schultz, and David Wells.

Sentiment

Score: 7

Explanation: The document reflects a positive development with the addition of an independent director and the strengthening of the risk committee, which is generally viewed favorably by investors.

Positives

• The addition of an independent director may enhance the board's oversight and governance.
• The consulting agreement with Ms. Autor could provide valuable expertise to the company.
• The appointment of Ms. Autor to the Risk Committee may strengthen the company's risk management capabilities.

Risks

• The consulting agreement can be terminated with 30 days' notice without cause, which could lead to a loss of Ms. Autor's services.
• The consulting agreement could create a potential conflict of interest if not managed properly.

Future Outlook

The newly appointed director will serve until the 2025 annual meeting of stockholders, and the consulting agreement is for a one-year period.

Industry Context

The appointment of an independent director is a common practice for publicly traded companies to enhance corporate governance and oversight.

Comparison to Industry Standards

• The appointment of an independent director is consistent with corporate governance best practices observed in similar publicly traded companies.
• The compensation structure for the new director appears to be in line with industry standards for board members.
• The formation of a Risk Committee is a standard practice for companies of this size and complexity, similar to companies like Teladoc Health and GoodRx.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an independent director positively, potentially increasing confidence in the company's governance.
• The addition of Ms. Autor to the Risk Committee may improve the company's risk management, benefiting all stakeholders.

Next Steps

• Ms. Autor will serve on the board until the 2025 annual meeting of stockholders.
• The consulting agreement will be filed as an exhibit to the company's Form 10-K for the year ended December 31, 2024.

Key Dates

Keywords

board of directors, independent director, corporate governance, risk committee, consulting agreement, executive appointment, Hims & Hers Health